IL158771A0 - Pharmaceutical compositions of adsorbates of amorphous drug - Google Patents
Pharmaceutical compositions of adsorbates of amorphous drugInfo
- Publication number
- IL158771A0 IL158771A0 IL15877102A IL15877102A IL158771A0 IL 158771 A0 IL158771 A0 IL 158771A0 IL 15877102 A IL15877102 A IL 15877102A IL 15877102 A IL15877102 A IL 15877102A IL 158771 A0 IL158771 A0 IL 158771A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- adsorbates
- amorphous drug
- amorphous
- drug
- Prior art date
Links
- 239000002156 adsorbate Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30026001P | 2001-06-22 | 2001-06-22 | |
PCT/IB2002/001792 WO2003000238A1 (en) | 2001-06-22 | 2002-05-21 | Pharmaceutical compositions of adsorbates of amorphous drug |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158771A0 true IL158771A0 (en) | 2004-05-12 |
Family
ID=23158346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15877102A IL158771A0 (en) | 2001-06-22 | 2002-05-21 | Pharmaceutical compositions of adsorbates of amorphous drug |
Country Status (29)
Country | Link |
---|---|
US (3) | US20030054037A1 (xx) |
EP (2) | EP2275091A1 (xx) |
JP (1) | JP4547148B2 (xx) |
KR (2) | KR100759635B1 (xx) |
CN (1) | CN1523979A (xx) |
AT (1) | ATE486586T1 (xx) |
AU (1) | AU2002302903B2 (xx) |
BG (1) | BG108489A (xx) |
BR (1) | BR0210519A (xx) |
CA (1) | CA2448825C (xx) |
CR (1) | CR7167A (xx) |
CZ (1) | CZ20033456A3 (xx) |
DE (1) | DE60238193D1 (xx) |
EA (1) | EA006777B1 (xx) |
EC (1) | ECSP034895A (xx) |
EE (1) | EE200400034A (xx) |
HU (1) | HUP0400281A3 (xx) |
IL (1) | IL158771A0 (xx) |
IS (1) | IS7018A (xx) |
MA (1) | MA27038A1 (xx) |
MX (1) | MXPA03010165A (xx) |
NO (1) | NO20035498D0 (xx) |
NZ (1) | NZ529490A (xx) |
OA (1) | OA12625A (xx) |
PL (1) | PL367674A1 (xx) |
SK (1) | SK15742003A3 (xx) |
TN (1) | TNSN03138A1 (xx) |
WO (1) | WO2003000238A1 (xx) |
ZA (1) | ZA200308735B (xx) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
KR20040083493A (ko) * | 2002-02-01 | 2004-10-02 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형 |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
WO2005023225A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Cilostazol adsorbate |
DE50306684D1 (de) * | 2003-11-18 | 2007-04-12 | Helm Ag | Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten |
EP1563833B1 (de) * | 2004-02-06 | 2006-11-02 | Helm AG | Pharmazeutische Zubereitungen mit amorphem Tibolon |
MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
BRPI0514753A (pt) * | 2004-08-31 | 2008-06-24 | Pfizer Prod Inc | formas de dosagem farmacêutica compreendendo um medicamento de baixa solubilidade e um polìmero |
GB2419094A (en) * | 2004-10-12 | 2006-04-19 | Sandoz Ag | Pharmaceutical composition of unpleasnt tasing active substances |
DE102004055229A1 (de) * | 2004-11-17 | 2006-05-18 | Heidelberger Druckmaschinen Ag | Zustandsabhängige Absicherung von Maschinen |
US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
EP1852118A1 (en) * | 2005-01-25 | 2007-11-07 | Kowa Company, Ltd. | Method for producing adsorptive porous body |
US9265731B2 (en) | 2005-01-28 | 2016-02-23 | Bend Research, Inc. | Drying of drug-containing particles |
WO2006082518A1 (en) * | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
WO2008122048A2 (en) | 2007-04-02 | 2008-10-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Removal of contrast agents from blood |
EP2129674A2 (en) * | 2007-04-03 | 2009-12-09 | Dr. Reddy's Laboratories Ltd. | Solid forms of pemetrexed |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
EP2187968A4 (en) | 2007-08-21 | 2013-02-20 | Univ Texas | THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS |
EP2072042A1 (en) * | 2007-12-21 | 2009-06-24 | Lek Pharmaceuticals D.D. | Active pharmaceutical ingredient on solid support, amorphous and with improved solubility |
AU2009224418B2 (en) * | 2008-03-11 | 2014-12-11 | Aska Pharmaceutical Co., Ltd. | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both |
CA2725484A1 (en) * | 2008-05-30 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Percutaneously absorbable preparation |
JP5670336B2 (ja) * | 2008-10-02 | 2015-02-18 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 全身性炎症の治療のためのポリマー吸着剤の投与 |
US8778401B2 (en) * | 2008-10-28 | 2014-07-15 | Agency For Science, Technology And Research | Mesoporous material excipients for poorly aqueous soluble ingredients |
KR101004205B1 (ko) * | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
WO2010092925A1 (ja) * | 2009-02-12 | 2010-08-19 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
US8685458B2 (en) * | 2009-03-05 | 2014-04-01 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
EP3130396B1 (en) | 2009-03-27 | 2021-03-17 | Bend Research, Inc. | Spray-drying process |
EP2238979A1 (en) * | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
PL2442791T3 (pl) | 2009-06-16 | 2020-05-18 | Pfizer Inc. | Postacie dawkowania apiksabanu |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
US20130203602A1 (en) * | 2010-03-11 | 2013-08-08 | Danmarks Tekniske Universitet | Supported biologically active compounds |
WO2011148253A2 (en) | 2010-05-25 | 2011-12-01 | Aurobindo Pharma Limited | Solid dosage forms of antipsychotics |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
PT2611530T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Aparelho de secagem por pulverização e métodos de utilização do mesmo |
EP2618924A1 (en) | 2010-09-24 | 2013-07-31 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
TWI590821B (zh) * | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
AU2012295397A1 (en) * | 2011-08-16 | 2014-02-20 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
CA2845284C (en) | 2011-08-18 | 2018-03-06 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors |
EP2760864B1 (en) | 2011-09-27 | 2018-01-24 | Dr. Reddy's Laboratories Ltd. | 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS |
EA201891397A1 (ru) * | 2014-02-05 | 2019-03-29 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
PT3212169T (pt) | 2014-10-31 | 2021-05-06 | Bend Res Inc | Processo para formar domínios ativos dispersos numa matriz |
WO2016204058A1 (ja) * | 2015-06-15 | 2016-12-22 | 住友化学株式会社 | 有機el素子の製造方法 |
CN113476408A (zh) * | 2021-07-23 | 2021-10-08 | 兆科药业(广州)有限公司 | 一种苯丁酸甘油酯颗粒剂及其制备方法与应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
JPS5942313A (ja) * | 1982-09-01 | 1984-03-08 | Teijin Ltd | ポリビニルポリピロリドンを用いた製剤 |
EP0129893B1 (en) * | 1983-06-28 | 1991-09-04 | Takeda Chemical Industries, Ltd. | Ground mixture |
US4581232A (en) * | 1983-07-20 | 1986-04-08 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4717565A (en) * | 1986-03-27 | 1988-01-05 | Warner-Lambert Company | Process for the preparation of medicament adsorbates |
US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US4711774A (en) * | 1986-03-27 | 1987-12-08 | Warner-Lambert Company | Medicament adsorbates with complex magnesium aluminum silicate and their preparation |
US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
US4835186A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
IE60458B1 (en) | 1989-10-26 | 1994-07-13 | Elan Corp Plc | Enhanced bioavailability adsorbates |
US5300302A (en) * | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5626878A (en) * | 1995-01-10 | 1997-05-06 | Warner Lambert Company | Reduction of electrostatic forces between magnesium trisilicate adsorbates |
SI9500059A (sl) | 1995-02-23 | 1996-08-31 | Lek Tovarna Farmacevtskih | Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba |
WO1996032126A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
AU6378796A (en) * | 1995-06-06 | 1996-12-24 | Warner-Lambert Company | Ranitidine salts on magnesium trisilicate as an adsorbate |
DE19532061A1 (de) * | 1995-08-31 | 1997-03-06 | Bayer Ag | N-Sulfonyliminodithioverbindungen |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
DE19627419A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Cycloalkano-pyridine |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
DE19704244A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
DE19704243A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | Neue 2-Amino-substituierte Pyridine |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
US6403587B1 (en) | 1997-02-26 | 2002-06-11 | Pfizer Inc. | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
WO1999014204A1 (en) | 1997-09-16 | 1999-03-25 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
DE19832159A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Substituierte Tetrahydro-naphthaline |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
DE19741399A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
DE19741400A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Benzyl-biphenyle |
CA2304763A1 (en) * | 1997-09-29 | 1999-04-08 | Pei Han | A fagopyrum cymosum (trev.) meisn composition, method to prepare and analyze the same and uses thereof |
UA57824C2 (uk) | 1998-02-05 | 2003-07-15 | Пфайзер Продактс Інк. | Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти) |
WO1999041237A1 (en) | 1998-02-13 | 1999-08-19 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
JPH11246404A (ja) | 1998-03-04 | 1999-09-14 | Taiho Yakuhin Kogyo Kk | 吸収を改善した医薬組成物 |
US20010025046A1 (en) | 1999-06-24 | 2001-09-27 | Rong(Ron) Liu | Self-emulsifying systems containing anticancer medicament |
EP1104290B1 (en) * | 1998-08-13 | 2010-03-31 | Cima Labs Inc. | Microemulsions as solid dosage forms for oral administration |
US6376481B2 (en) * | 1998-09-02 | 2002-04-23 | Mcneil-Ppc, Inc. | Sterol esters in tableted solid dosage forms |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
CA2345108A1 (en) | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
GEP20094661B (en) | 1998-09-25 | 2009-03-25 | Pharmacia Corp | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY |
ES2310164T3 (es) * | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
PT1165051E (pt) * | 1999-03-19 | 2003-11-28 | Ranbaxy Lab Ltd | Processo para a preparacao de uma forma de dosagem oral biodisponivel de cefuroxima axetil |
KR100342943B1 (ko) | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
AR028253A1 (es) * | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
PE20011184A1 (es) * | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US6602523B1 (en) * | 2000-08-17 | 2003-08-05 | Technology Holding, Llc. | Composite material and process for increasing bioavailability and activity of a beneficial agent |
US6596262B2 (en) * | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
-
2002
- 2002-05-21 WO PCT/IB2002/001792 patent/WO2003000238A1/en active IP Right Grant
- 2002-05-21 AU AU2002302903A patent/AU2002302903B2/en not_active Ceased
- 2002-05-21 EE EEP200400034A patent/EE200400034A/xx unknown
- 2002-05-21 EA EA200301279A patent/EA006777B1/ru not_active IP Right Cessation
- 2002-05-21 EP EP10175652A patent/EP2275091A1/en not_active Withdrawn
- 2002-05-21 TN TNPCT/IB2002/001792A patent/TNSN03138A1/en unknown
- 2002-05-21 CN CNA028125037A patent/CN1523979A/zh active Pending
- 2002-05-21 CA CA002448825A patent/CA2448825C/en not_active Expired - Lifetime
- 2002-05-21 CZ CZ20033456A patent/CZ20033456A3/cs unknown
- 2002-05-21 BR BR0210519-5A patent/BR0210519A/pt not_active IP Right Cessation
- 2002-05-21 OA OA1200300326A patent/OA12625A/en unknown
- 2002-05-21 SK SK1574-2003A patent/SK15742003A3/sk not_active Application Discontinuation
- 2002-05-21 KR KR1020067021756A patent/KR100759635B1/ko not_active IP Right Cessation
- 2002-05-21 HU HU0400281A patent/HUP0400281A3/hu unknown
- 2002-05-21 AT AT02730596T patent/ATE486586T1/de not_active IP Right Cessation
- 2002-05-21 IL IL15877102A patent/IL158771A0/xx unknown
- 2002-05-21 JP JP2003506885A patent/JP4547148B2/ja not_active Expired - Fee Related
- 2002-05-21 PL PL02367674A patent/PL367674A1/xx not_active Application Discontinuation
- 2002-05-21 EP EP02730596A patent/EP1404302B1/en not_active Revoked
- 2002-05-21 DE DE60238193T patent/DE60238193D1/de not_active Expired - Lifetime
- 2002-05-21 MX MXPA03010165A patent/MXPA03010165A/es active IP Right Grant
- 2002-05-21 NZ NZ529490A patent/NZ529490A/en unknown
- 2002-05-21 KR KR1020037017032A patent/KR100768766B1/ko not_active IP Right Cessation
- 2002-06-17 US US10/173,987 patent/US20030054037A1/en not_active Abandoned
-
2003
- 2003-11-10 IS IS7018A patent/IS7018A/is unknown
- 2003-11-10 ZA ZA200308735A patent/ZA200308735B/en unknown
- 2003-11-25 CR CR7167A patent/CR7167A/es not_active Application Discontinuation
- 2003-12-10 NO NO20035498A patent/NO20035498D0/no not_active Application Discontinuation
- 2003-12-11 EC EC2003004895A patent/ECSP034895A/es unknown
- 2003-12-11 MA MA27435A patent/MA27038A1/fr unknown
- 2003-12-22 BG BG108489A patent/BG108489A/bg unknown
-
2006
- 2006-12-04 US US11/566,408 patent/US8703199B2/en active Active
-
2008
- 2008-07-28 US US12/180,769 patent/US8389006B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158771A0 (en) | Pharmaceutical compositions of adsorbates of amorphous drug | |
WO2005011635A3 (en) | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials | |
AU2002360530A1 (en) | (5) helicene AND dibenzofluorene MATERIALS FOR USE IN ORGANIC LIGHT EMITTING DEVICES | |
CA2395331A1 (en) | Pharmaceutical compositions providing enhanced drug concentrations | |
AU2003253443A1 (en) | Monoaminofluorene compound and organic light-emitting device using the same | |
AU2003278233A1 (en) | Implantable mechanical device with adjustable geometry | |
AU2003220082A1 (en) | Thermionic vacuum diode device with adjustable electrodes | |
GEP20074210B (en) | Tropane derivatives as ccr5 modulators | |
AU2002365360A1 (en) | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same | |
AU2003291344A1 (en) | Patient support device with shoulder depression device | |
AU1904300A (en) | Improved organic led device | |
AU2003276908A1 (en) | Absorbent article with containment flaps | |
AU2002339150A1 (en) | Container with organic light emitting device | |
AU2003220006A1 (en) | Styrene-acrylate copolymer composition suitable for surface size | |
AU2003286847A1 (en) | Solid state inducting device | |
AU2002352500A1 (en) | Absorbent articles with absorbent pad gapping | |
USD495082S1 (en) | Lamp with adjustable arm | |
EP1697431B8 (en) | Boron-containing polymer compound and organic light emitting device using the same | |
AU2003292984A1 (en) | Amino-substituted oligothiophenes as organic semiconductor materials | |
AU2003223423A1 (en) | Bipolar transistor with graded base layer | |
EP1398497B8 (en) | Fuel injection device having injection hole plate | |
USD484229S1 (en) | Air freshener device | |
AU2003278456A1 (en) | Gum base composition | |
ATE469902T1 (de) | Amorphe substanz eines tricyclischen triazolobenzazepinderivats | |
AU4436300A (en) | Administration device for lighting fixtures |